Last reviewed · How we verify
Chlorure de sodium
Chlorure de sodium is a Electrolyte replacement agent Small molecule drug developed by Centre Hospitalier Universitaire Dijon. It is currently in Phase 3 development for Hyponatremia (low sodium levels), Dehydration and fluid loss, Electrolyte imbalance correction.
Sodium chloride replaces lost electrolytes and restores osmotic balance in body fluids.
Sodium chloride replaces lost electrolytes and restores osmotic balance in body fluids. Used for Hyponatremia (low sodium levels), Dehydration and fluid loss, Electrolyte imbalance correction.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chlorure de sodium |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | Electrolyte replacement agent |
| Modality | Small molecule |
| Therapeutic area | Electrolyte/Fluid Management |
| Phase | Phase 3 |
Mechanism of action
Sodium chloride is an essential electrolyte that maintains proper fluid balance, nerve conduction, and muscle contraction. It is used clinically to correct hyponatremia, dehydration, and electrolyte imbalances by restoring sodium and chloride ions to normal physiological levels. The drug works osmotically to regulate water distribution between intracellular and extracellular compartments.
Approved indications
- Hyponatremia (low sodium levels)
- Dehydration and fluid loss
- Electrolyte imbalance correction
- Saline solution for intravenous or oral rehydration
Common side effects
- Hypernatremia (excessive sodium)
- Fluid overload
- Phlebitis (at IV injection site)
- Nausea
Key clinical trials
- Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock (PHASE3)
- tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (PHASE3)
- Cognitive Biases Under Ketamine (NA)
- The Effect of Paracetamol on Brain Temperature (PHASE4)
- The Tap Block Technique Via the Anterior Approach in Elective Surgery of the Spine (PHASE4)
- Oral Sodium Blood Pressure in Normal Weight, Overweight and Obese Volunteers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorure de sodium CI brief — competitive landscape report
- Chlorure de sodium updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI
Frequently asked questions about Chlorure de sodium
What is Chlorure de sodium?
How does Chlorure de sodium work?
What is Chlorure de sodium used for?
Who makes Chlorure de sodium?
What drug class is Chlorure de sodium in?
What development phase is Chlorure de sodium in?
What are the side effects of Chlorure de sodium?
Related
- Drug class: All Electrolyte replacement agent drugs
- Manufacturer: Centre Hospitalier Universitaire Dijon — full pipeline
- Therapeutic area: All drugs in Electrolyte/Fluid Management
- Indication: Drugs for Hyponatremia (low sodium levels)
- Indication: Drugs for Dehydration and fluid loss
- Indication: Drugs for Electrolyte imbalance correction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing